Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence-Reference-Cited by-同舟云学术

Artesunate, imatinib, and infliximab in COVID‐19: A rapid review and meta‐analysis of current evidence

Author:

Amani Bahman¹^ORCID,Zareei Sara²^ORCID,Amani Behnam¹^ORCID,Zareei Mahsa³^ORCID,Zareei Neda⁴^ORCID,Shabestan Rouhollah⁵^ORCID,Akbarzadeh Arash⁵^ORCID

Affiliation:

1. Department of Health Management and Economics, School of Public Health Tehran University of Medical Sciences Tehran Iran

2. Department of Cell & Molecular Biology, Faculty of Biological Sciences Kharazmi University Tehran Iran

3. Department of Health Services Management, School of Health Management and Information Sciences Iran University of Medical Sciences Tehran Iran

4. Shiraz Transplant Research Center Shiraz University of Medical Sciences Shiraz Iran

5. Department of Biostatistics and Epidemiology, School of Public Health Tehran University of Medical Sciences Tehran Iran

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

Reference74 articles.

3. WHO.

5. OrganizationWH World Health Organization. COVID‐19 weekly epidemiological update (pp. 55) August 31 2021.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

5. COVID-19 as a Global Health Crisis;Nursing Practice during COVID-19: Preparation, Education and Support;2024